Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
---|---|---|---|---|---|---|---|
Net Debt | ($26.2M) | ($9,681.0K) | ($12.7M) | ($763.4M) | ($545.4M) | ($238.0M) | ($221.5M) |
Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
---|---|---|---|---|---|---|---|
% growth | 281.0 0.0% | 462.3 64.5% | 672.9 45.6% | 1,472.0 118.8% | 1,096.6 (25.5%) | 1,260.5 15.0% | 1,371.1 8.8% |
Cost of Goods Sold (COGS) | 0.0 | 449.7 | 590.1 | 1,551.2 | 993.1 | 1,004.6 | 1,006.3 |
% margin | 281.0 100.0% | 12.6 2.7% | 82.8 12.3% | (79.2) (5.4%) | 103.5 9.4% | 256.0 20.3% | 364.8 26.6% |
Operating Expenses | 476.0 | 195.8 | 175.5 | 557.8 | 390.1 | 461.3 | 410.6 |
Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative Expenses (SG&A) | 187.3 | 187.3 | 192.1 | 445.7 | 482.4 | 440.2 | 408.9 |
% margin | (185.8) (66.1%) | (183.2) (39.6%) | (92.7) (13.8%) | (637.0) (43.3%) | (286.7) (26.1%) | (205.3) (16.3%) | (45.7) (3.3%) |
Interest Income | 7.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
Interest Expense | 0.0 | 39.1 | 57.1 | 16.9 | 1.4 | 0.0 | 0.0 |
Pre-tax Income | (201.9) | (363.7) | (136.4) | (587.8) | (254.6) | (210.1) | (46.3) |
% effective tax rate | (16.1) 8.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
% margin | (201.9) (71.9%) | (363.7) (78.7%) | (136.4) (20.3%) | (587.8) (39.9%) | (339.6) (31.0%) | (213.4) (16.9%) | (43.0) (3.1%) |
EPS | (4.81) | (0.90) | (0.23) | (1.25) | (0.71) | (0.45) | (0.08) |
Diluted EPS | (4.81) | (0.90) | (0.23) | (1.25) | (0.71) | (0.45) | (0.08) |
% margin | (16.1) (5.7%) | (324.1) (70.1%) | (78.7) (11.7%) | (569.6) (38.7%) | (252.0) (23.0%) | (207.6) (16.5%) | (44.9) (3.3%) |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of today, Clover Health Investments, Corp.'s last 12-month Net Debt is ($221.5M), based on the financial report for Dec 31, 2024 (Q4’2024).
Over the last year, Clover Health Investments, Corp.'s Net Debt growth was (5.7%). The average annual Net Debt growth rates for Clover Health Investments, Corp. have been (28.5%) over the past three years, 87.0% over the past five years.
Over the last year, Clover Health Investments, Corp.'s Net Debt growth was (5.7%), which is lower than industry growth of (0.3%). It indicates that Clover Health Investments, Corp.'s Net Debt growth is Good.